<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134468</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC10219</org_study_id>
    <secondary_id>IRB833642</secondary_id>
    <nct_id>NCT04134468</nct_id>
  </id_info>
  <brief_title>MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy
      treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors.
      Subjects will received Gemcitabine, Abraxane and PEGPH20.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Halozyme halted development of PEGPH20 following Phase 3 failure.
  </why_stopped>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">November 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lesion size</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>Change in lesion size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a complete R0 surgical resection</measure>
    <time_frame>at time of surgery</time_frame>
    <description>Proportion of patients achieving a complete R0 surgical resection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegvorhyaluronidase alfa</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
    <other_name>PEGPH20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form

          2. Capable of giving informed consent.

          3. Ability and willingness to comply with the protocol including all scheduled MRI
             studies and paired tumor biopsies

          4. Aged â‰¥ 18 years.

          5. borderline or unresectable pancreatic adenocarcinoma without distant metastatic
             disease.

          6. ECOG PS of 0 or 1

          7. Must have adequate organ and hematopoietic function

          8. Female and Males must use an approved contraceptive method

        Exclusion Criteria:

          1. Received prior therapy for pancreatic adenocarcinoma

          2. History of deep vein thrombosis (DVT) or pulmonary embolism (PE)

          3. Contraindication to therapeutic anticoagulation or heparin

          4. Intolerance to dexamethasone

          5. Contraindication to MRI or unwillingness to undergo all scheduled MRI exams

          6. Known or suspected brain metastasis

          7. Significant cardiovascular disease such as current New York Heart Associate Class
             III/IV heart failure, myocardial infarction or stroke within 6 months prior to
             enrollment

          8. A second primary malignancy that, in the judgment of the investigator, may affect the
             interpretation of results

          9. Any illness or condition that in the opinion of the investigator may affect the safety
             of the subject or the evaluation of any study endpoint

         10. Active bacterial or fungal infection requiring IV therapy at the start of protocol
             treatment

         11. Subjects may not receive concomitant anticancer agents or radiation.

         12. Female subjects who are pregnant or nursing

         13. Pre-existing peripheral neuropathy &gt; CTCAE Grade 2.

         14. Known allergy to hyaluronidase

         15. Current use of megestrol acetate (use within 10 days of Day 1)

         16. Inability to comply with study and follow-up procedures as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Karasic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

